<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122586">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01767272</url>
  </required_header>
  <id_info>
    <org_study_id>PPT2</org_study_id>
    <nct_id>NCT01767272</nct_id>
  </id_info>
  <brief_title>Dose Proportionality of Fexofenadine in Healthy Human Egyptian Volunteers</brief_title>
  <acronym>DPF</acronym>
  <official_title>Dose Proportionality of Fexofenadine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <authority>Egypt: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study was adopted to evaluate the pharmacokinetics and dose linearity of
      fexofenadine after oral administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study was adopted to evaluate the pharmacokinetics and dose linearity of
      fexofenadine after administration of single oral doses of 60 to 360 mg in an open-label,
      five-way crossover study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Tolerability</measure>
    <time_frame>Participants will be followed for the duration of study, an expected average of 5 weeks.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Tolerability was assessed based on changes in vital signs (temperature, blood pressure, pulse, and heart rate), measured before dosing in each period and approximately every 4 hours thereafter, and laboratory tests (hematology, biochemistry, liver function, and urinalysis), and performed at baseline and at the end of the study. In addition, a physician questioned volunteers about any adverse events occurring during the study, addressed them as necessary, and recorded them on the appropriate form. This physician was not blinded to treatment, but had no involvement in the study.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>fexofenadine 60 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>First dose strength</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fexofenadine 120 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Second dose strength</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fexofenadine 180 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Third dose strength</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fexofenadine 240 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fourth dose strength</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fexofenadine 360 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fifth dose strength</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fexofenadine</intervention_name>
    <description>fexofenadine brand name</description>
    <arm_group_label>fexofenadine 60 mg</arm_group_label>
    <arm_group_label>fexofenadine 120 mg</arm_group_label>
    <arm_group_label>fexofenadine 180 mg</arm_group_label>
    <arm_group_label>fexofenadine 240 mg</arm_group_label>
    <arm_group_label>fexofenadine 360 mg</arm_group_label>
    <other_name>Telfast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years old and not more than 45 healthy male volunteers

          -  Actual weight no more than Â± 30% from ideal body weight based on sex, height, and
             body frame

          -  Who had passed all the screening parameters

          -  Free of any drug exposure known to interfere with the pharmacokinetics or assay of
             fexofenadine for at least 10 days prior to the study

          -  Who had to be able to communicate effectively with study personnel, be literate, and
             able to give consent.

        Exclusion Criteria:

          -  A clinically significant abnormal physical exam, medical history, or laboratory
             studies

          -  If they showed a sitting SBP of &gt;140 or &lt;100 mmHg, DBP &gt; 90 or &lt;60mm Hg, or a pulse
             rate of &gt; 95 or &lt; 50 beats/min at screening

          -  A history of serious intolerance, allergy, or sensitivity to fexofenadine

          -  The use of any prescription drug within the previous month or use of any
             over-the-counter medication (with the exception of acetaminophen) within the past 14
             days

          -  A history of blood dyscrasias

          -  A history of alcohol or drug abuse within the past year

          -  Donation of blood during the 8 weeks prior to the study or plans to donate blood
             during or within 8 weeks of completing the study

          -  Unable to tolerate vein puncture and multiple blood samplings

          -  Any surgical/medical condition that might alter drug absorption, distribution,
             metabolism, or excretion

          -  Cannot follow instructions, in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 10, 2013</lastchanged_date>
  <firstreceived_date>January 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Damanhour University</investigator_affiliation>
    <investigator_full_name>Sally Helmy, PhD, CPHQ</investigator_full_name>
    <investigator_title>Lecturer of Pharmaceutics, Faculty of Pharmacy</investigator_title>
  </responsible_party>
  <keyword>Fexofenadine</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Linearity</keyword>
  <keyword>HPLC</keyword>
  <keyword>Dose proportionality of fexofenadine in Egyptian volunteers</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Terfenadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
